Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea

Authors
Lee, Kyong JooCho, Jae HeeLee, Sang HyubSong, Si YoungLee, Kwang HyukJeong, SeokRyu, Ji KonWoo, Sang MyungBang, SeungminLee, Jong KyunLee, Tae HoonPaik, Woo HyunKim, Yong TaeLee, Woo Jin
Issue Date
Oct-2017
Publisher
Springer Verlag
Keywords
Everolimus; Pancreatic neuroendocrine tumor; World Health Organization classification; Tumor grade; Prognosis
Citation
Cancer Chemotherapy and Pharmacology, v.80, no.4, pp 799 - 805
Pages
7
Journal Title
Cancer Chemotherapy and Pharmacology
Volume
80
Number
4
Start Page
799
End Page
805
URI
https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/7188
DOI
10.1007/s00280-017-3421-7
ISSN
0344-5704
1432-0843
Abstract
Everolimus is a standard treatment option for advanced pancreatic neuroendocrine tumors (pNETs). This multicenter study evaluated the efficacy and safety of everolimus in low and intermediate grade advanced pNETs. Tumors were graded according to the World Health Organization 2010 classification system. Patients with low or intermediate grade pNETs who received everolimus as first- or second-line chemotherapy between 2002 and 2014 were included. A total of 40 patients with metastatic or recurrent pNETs were included in this study. The median age was 54.5 years (range 19-83 years). Twelve patients (30%) experienced recurrence. There were 11 patients (27.5%) with low grade pNETs and 29 (72.5%) with intermediate. Everolimus was administered as first-line therapy in 30 patients (75%) and as second-line therapy in 10 patients (25%). The median progression-free survival (PFS) of patients with low and intermediate grade pNETs was significantly different (median not reached vs. 11 months, P = 0.015). On multivariate analysis, tumor grade (intermediate grade; HR 6.52, 95% CI 1.31-32.27, P = 0.022) was the only independent prognostic factor for PFS in pNETs. The most common adverse events were stomatitis, skin rash, and anemia. World Health Organization 2010 grade is the most important determinant for PFS in patients undergoing everolimus treatment for pNETs with an acceptable incidence of adverse events.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Internal Medicine > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Lee, Tae hoon photo

Lee, Tae hoon
College of Medicine (Department of Internal Medicine)
Read more

Altmetrics

Total Views & Downloads

BROWSE